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HighlightsCircMAN2B2 is highly expressed in gastric cancer tissues;CircMAN2B2 silence suppresses gastric cancer cells growth and migration;CircMAN2B2 negatively regulates miR‐145;CircMAN2B2 exerts its oncogenic function through miR‐145;CircMAN2B2 regulates PI3K/AKT and JNK pathways through miR‐145.

1. INTRODUCTION {#jcla23215-sec-0006}
===============

Gastric carcinoma (GC) is one of the top ten most common malignant tumors around the world. As estimated by Siegel and his colleagues, there are 28 000 cases and 10 960 GC‐related death occurred in United States at 2017.[1](#jcla23215-bib-0001){ref-type="ref"} At present, surgery is still the main method to cure GC in the case of early diagnosed. But, most GC patients are diagnosed in the late stages since the symptoms of GC are generally vague, non‐specific and may not occur until late in disease progression.[2](#jcla23215-bib-0002){ref-type="ref"} For those patients, unresectable therapeutic options like chemotherapy and radiation are always recommended, but unfortunately, this cancer is unlikely to be cured. What\'s worse, the high recurrence and metastasis of GC[3](#jcla23215-bib-0003){ref-type="ref"}, [4](#jcla23215-bib-0004){ref-type="ref"} make itself to be more intractable with lower overall survival. So, there is clinical significance to extensively investigate the deep pathogenesis of GC, which may be helpful for investigating novel treatment strategy.

Circular RNAs (circRNAs), formed by alternative splicing of pre‐mRNA transcripts, are stable and widespread non‐coding RNAs in human cells. Current studies have shown that circRNAs play important regulatory roles in a variety of diseases, such as cardiovascular diseases,[5](#jcla23215-bib-0005){ref-type="ref"} nervous system diseases,[6](#jcla23215-bib-0006){ref-type="ref"} hypertension,[7](#jcla23215-bib-0007){ref-type="ref"} and preeclampsia.[8](#jcla23215-bib-0008){ref-type="ref"} In addition, circRNAs are widely involved in the onset and progression of human cancers, including GC.[9](#jcla23215-bib-0009){ref-type="ref"} As reported by Shao et al, 308 circRNAs were found to be differentially expressed in GC, among which 34.74% was up‐regulated and 65.26% was down‐regulated.[10](#jcla23215-bib-0010){ref-type="ref"} More than that, circRNAs have clinical significance in treating GC. For the selected examples, silence of circCACTIN may suppress the growth, migration and invasion of GC cells.[11](#jcla23215-bib-0011){ref-type="ref"} CircMAN2B2 (circRNA ID: hsa_circRNA_0069086) is a newly discovered circRNA that consists of two exons of 291 nucleotides in length. To date, the oncogenic function of circMAN2B2 toward lung cancer [12](#jcla23215-bib-0012){ref-type="ref"} and glioma [13](#jcla23215-bib-0013){ref-type="ref"} has been revealed. Nonetheless, the role of circMAN2B2 in GC is still unclear.

MicroRNAs (miRNAs) are recently discovered single‐strand non‐coding RNAs that are as small as 19‐22 nucleotides. In general, they are participated in regulating the expression of target genes at post‐transcriptional level. It is recently recognized that miRNAs play significant roles in the development of human cancers, as they acted as either oncogenes or tumor suppressors.[14](#jcla23215-bib-0014){ref-type="ref"}, [15](#jcla23215-bib-0015){ref-type="ref"} In GC, miR‐145 expression was found to be down‐expressed and was associated with poor survival rate.[16](#jcla23215-bib-0016){ref-type="ref"} Moreover, miR‐145 acted as a tumor suppressor in GC through controlling tumor growth, chemo‐resistance, and metastasis.[17](#jcla23215-bib-0017){ref-type="ref"}, [18](#jcla23215-bib-0018){ref-type="ref"}

In the present paper, in vitro experiments were carried out to reveal the role of circMAN2B2 in the growth and migration of GC cells. Besides that, the regulatory impact of circMAN2B2 on miR‐145 expression was studied to uncover the deep mechanisms of circMAN2B2's function.

2. MATERIALS AND METHODS {#jcla23215-sec-0007}
========================

2.1. Clinical specimens {#jcla23215-sec-0008}
-----------------------

Twenty‐five pairs of GC tissues and the paracancerous tissues were harvested from patients with GC which are attained from The Chinese People\'s Liberation Army Navy 971 Hospital (Qingdao, China). This experiment was approved by the Ethics Committee of The Chinese People\'s Liberation Army Navy 971 Hospital. These clinical specimens were harvested during tumor resection, before which none of them received any other therapies. Written informed consents were signed before the usage of the clinical specimens from each individual. Clinical specimens were washed with ice‐cold PBS and stored at −80°C until use.

2.2. Cells {#jcla23215-sec-0009}
----------

Two GC cell lines (SNU‐16 and AGS) were brought from ATCC. SNU‐16 and AGS cells were respectively grown in RPMI‐1640 medium (ATCC) and F‐12K medium (ATCC), which are supplemented with 10% fetal bovine serum (Gibco). Cells were maintained at 37°C in 95% air and 5% CO~2~.

2.3. Cell transfection {#jcla23215-sec-0010}
----------------------

siRNA specific against circMAN2B2 (si‐circMAN2B2) was designed and purchased from Biomics Biotechnologies. Non‐targeting sequence was used as siRNA control. MiR‐145 inhibitor and the negative control (NC inhibitor) were brought from GenePharma. Lipofectamine 2000 (Invitrogen) was utilized for transfection which was lasted for 48 hours. The sequence of si‐circMAN2B2 was displayed as follows: 5′‐TCGCAGGTCCAGCACCATGAT‐3′.

2.4. qRT‐PCR {#jcla23215-sec-0011}
------------

Total RNAs were harvested from clinical specimens and the transfected cells through utilizing TRIzol reagent (Invitrogen). Then, the concentration of extracted RNA was detected through a NanoDrop Spectrophotometer (NanoDrop Technologies) at 260 nm/280 nm. For the test of circMAN2B2, PrimeScript^™^ RT reagent Kit and TB Green Premix Ex Taq II (Takara) were utilized for inverse transcription and quantitative PCR, respectively. For the test of miR‐145, Mir‐X^™^ miRNA First Strand Synthesis Kit and Mir‐X^™^ miRNA qRT‐PCR TB Green^™^ Kit were utilized (Takara). GAPDH and U6 served as reference controls for circMAN2B2 and miR‐145. The primer sequences used in the study were displayed as follows: circMAN2B2, forward 5′‐CCCAACATGAGTGAGCCTGT‐3′, reverse 5′‐GCACCGAGGCATTGAAGAAC‐3′; miR‐145, forward 5′‐ACACTCCAGCTGGGGTCCAGTTTTCCCAGGA‐3′, reverse 5′‐TGGTGTCGTGGAGTCG‐3′; GADPH, forward 5′‐GTCAACGGATTTGGTCTGTATT‐3′, reverse 5′‐AGTCTTCTGGGTGGCAGTGAT‐3′; U6, forward 5′‐CTCGCTTCGGCAGCACA‐3′, and reverse 5′‐AACGCTTCACGAATTTGCGT‐3′. Real‐time‐PCR reactions were performed by the ABI7300 cycler (Applied Biosystems) through ABI7300 software.

2.5. CCK‐8 assay {#jcla23215-sec-0012}
----------------

The transfected SNU‐16 and AGS cells in 96‐well plates (5000 cells/well) were cultured at 37°C for 48 hours. Then, the culture medium was replaced and 10 μL CCK‐8 solution (Dojindo Molecular Technologies) was added. Following incubation at 37°C for 4 hours, the samples were tested under a Microplate Reader (Bio‐Rad) at 450 nm.

2.6. Colony formation assay {#jcla23215-sec-0013}
---------------------------

The transfected SNU‐16 and AGS cells in 6‐well plates (500 cells/well) were cultured at 37°C for 2 weeks. Then, cells were fixed with 4% paraformaldehyde fix solution (Sangon Biotech) and stained with 0.5% crystal violet (Sangon Biotech). Survival fractions were calculated according to the following formula: $\text{survival}\,\text{fractions}\left( \% \right) = \frac{\left( {\text{stained}\,\text{cells}\,\text{in}\,\text{experimental}\,\text{group}} \right)}{\left( {\text{stained}\,\text{colonies}\,\text{in}\,\text{control}\,\text{group}} \right)} \times 100\%.$

2.7. Apoptosis assay {#jcla23215-sec-0014}
--------------------

The transfected SNU‐16 and AGS cells were harvested, and the apoptosis rate of 1 × 10^5^ cells per sample was tested by utilizing Annexin V‐FITC/PI Apoptosis Detection Kit (Sangon Biotech) according to the manufacture\'s instruction. Flow cytometer detection was done in FACS Calibur (Becton Dickson) by counting FITC‐positive and PI‐negative cells through Cell Quest Research Software (Becton Dickinson).

2.8. Migration assay {#jcla23215-sec-0015}
--------------------

Twenty four‐well Transwell chambers with 8 μm pore size (BD Biosciences) were used. The transfected SNU‐16 and AGS cells (1 × 10^5^ cells/well) were suspended in serum‐free culture medium and placed on the upper side of the well. The lower side was filled with the complete culture medium. Following incubation at 37°C for 24 hours, the cells in the upper side were removed, and those in the lower side were stained by 0.5% crystal violet (Sangon Biotech) for 10 minutes. The migration rate was calculated by counting stained cells under IX73 inverted microscope (Olympus).

2.9. Protein immunoblot {#jcla23215-sec-0016}
-----------------------

Total proteins were harvested from the transfected SNU‐16 and AGS cells by utilizing RIPA buffer (Sangon Biotech) and quantified through BCA^™^ Protein Assay Kit (Pierce). Immunoblotting was done by using primary antibodies specific against cleaved‐caspase‐3 (orb126609, Biorbyt), cleaved‐caspase‐9 (orb227889), MMP‐2 (orb101824), MMP‐9 (orb315177), PI3K (orb395443), p‐PI3K (orb106105), AKT (orb29949), p‐AKT (orb344456), JNK (orb38050), p‐JNK (orb184488), c‐Jun (orb97352), p‐c‐Jun (orb184488), and β‐actin (orb86987). Target bands were developed by EasyBlot ECL kit (Sangon Biotech), and the gray level of the bands was analyzed by Image Lab^™^ Software (Bio‐Rad).

2.10. Statistics {#jcla23215-sec-0017}
----------------

Data were presented as mean ± SD. Statistics were done in SPSS 19.0 software. Comparison was done by utilizing one‐way ANOVA or Student *t* test. Statistical differences were set at *P* \< .05 and indicated as asterisks in figures.

3. RESULTS {#jcla23215-sec-0018}
==========

3.1. circMAN2B2 was highly expressed in GC tissues {#jcla23215-sec-0019}
--------------------------------------------------

qRT‐PCR analysis was utilized for testing the expression of circMAN2B2 in 25 pairs of GC tissues. As related to paracancerous tissues, level of circMAN2B2 in GC tissues was much higher (*P* \< .05, Figure [1](#jcla23215-fig-0001){ref-type="fig"}).

![CircMAN2B2 was highly expressed in gastric carcinoma (GC) tissues. qRT‐PCR analysis was utilized for testing the expression of circMAN2B2 in 25 pairs of GC tissues (T) and paracancerous non‐tumor tissues (NT). \**P* \< .05](JCLA-34-e23215-g001){#jcla23215-fig-0001}

3.2. Silence of circMAN2B2 suppressed the growth of GC cells {#jcla23215-sec-0020}
------------------------------------------------------------

siRNA specific against circMAN2B2 was transfected into two GC cell lines (SNU‐16 and AGS) to see the effect of circMAN2B2 on the growth of GC cells. Data presented in Figure [2](#jcla23215-fig-0002){ref-type="fig"}A showed that, circMAN2B2 expression was successfully repressed by siRNA transfection (*P* \< .05). As compared with si‐NC transfection, transfection of cells with si‐circMAN2B2 significantly declined cell viability (*P* \< .05, Figure [2](#jcla23215-fig-0002){ref-type="fig"}B), survival fraction (*P* \< .05, Figure [2](#jcla23215-fig-0002){ref-type="fig"}C), but induced apoptosis (*P* \< .05, Figure [2](#jcla23215-fig-0002){ref-type="fig"}D). Meanwhile, the cleavage of caspase −3 and −9 was evoked by si‐circMAN2B2 transfection as relative to si‐NC transfection (*P* \< .05, Figure [2](#jcla23215-fig-0002){ref-type="fig"}E‐G).

![Silence of circMAN2B2 suppressed the growth of GC cells. SNU‐16 and AGS cells were transfected with nothing, si‐NC or si‐circMAN2B2. A, Transfection efficiency was verified by qRT‐PCR analysis which tested by expression of circMAN2B2. B, Cell viability, (C) survival, (D) apoptosis, and (E‐G) expression of caspases were respectively examined by CCK‐8 assay, colony formation assay, flow cytometry, and Western blot. \**P* \< .05](JCLA-34-e23215-g002){#jcla23215-fig-0002}

3.3. Silence of circMAN2B2 suppressed the migration of GC cells {#jcla23215-sec-0021}
---------------------------------------------------------------

Also, the role of circMAN2B2 in the migration of GC cells was evaluated. As seen in Figure [3](#jcla23215-fig-0003){ref-type="fig"}A, the migration of both SNU‐16 and AGS cells was repressed by transfection with si‐circMAN2B2, as relative to si‐NC (*P* \< .05). Consistently, levels of migration‐related proteins (MMP‐2 and MMP‐9) were declined by transfection with si‐circMAN2B2, as relative to si‐NC (*P* \< .05, Figure [3](#jcla23215-fig-0003){ref-type="fig"}B‐D).

![Silence of circMAN2B2 suppressed the migration of GC cells. SNU‐16 and AGS cells were transfected with nothing, si‐NC or si‐circMAN2B2. A, Cell migration and (B‐D) expression of MMPs were respectively examined by Transwell assay and Western blot. \**P* \< .05](JCLA-34-e23215-g003){#jcla23215-fig-0003}

3.4. Silence of circMAN2B2 acted GC cells through regulating miR‐145 {#jcla23215-sec-0022}
--------------------------------------------------------------------

The expression change of miR‐145 in GC cells following transfection with si‐circMAN2B2 was tested. As qRT‐PCR data shown in Figure [4](#jcla23215-fig-0004){ref-type="fig"}A, miR‐145 expression was significantly elevated by si‐circMAN2B2 as relative to si‐NC (*P* \< .05). So, miR‐145 might be one of the downstream genes of circMAN2B2. To verify the authenticity of this hypothesis, miR‐145 expression in SNU‐16 and AGS cells was silenced by transfection with the specific inhibitor. Transfection efficiency shown in Figure [4](#jcla23215-fig-0004){ref-type="fig"}B demonstrated that, miR‐145 expression was successfully declined by miR‐145 inhibitor as relative to NC inhibitor (*P* \< .05).

![Silence of circMAN2B2 elevated miR‐145 expression. A, SNU‐16 and AGS cells were transfected with nothing, si‐NC or si‐circMAN2B2. B, SNU‐16 and AGS cells were transfected with nothing, NC inhibitor or miR‐145 inhibitor. miR‐145 expression was examined by qRT‐PCR. \**P* \< .05](JCLA-34-e23215-g004){#jcla23215-fig-0004}

Following experiments found that, co‐transfection of cells with si‐circMAN2B2 and miR‐145 inhibitor significantly increased cell viability (*P* \< .05, Figure [5](#jcla23215-fig-0005){ref-type="fig"}A), survival fraction (*P* \< .05, Figure [5](#jcla23215-fig-0005){ref-type="fig"}B), while repressed apoptosis (*P* \< .05, Figure [5](#jcla23215-fig-0005){ref-type="fig"}C) and the cleavage of caspases (*P* \< .05, Figure [5](#jcla23215-fig-0005){ref-type="fig"}D‐F), as compared to co‐transfection with si‐circMAN2B2 plus NC inhibitor. Meanwhile, migration (*P* \< .05, Figure [6](#jcla23215-fig-0006){ref-type="fig"}A) and the expression of relative proteins (*P* \< .05, Figure [6](#jcla23215-fig-0006){ref-type="fig"}B‐D) were elevated by co‐transfection with si‐circMAN2B2 and miR‐145 inhibitor as compared to co‐transfection with si‐circMAN2B2 plus NC inhibitor.

![Silence of circMAN2B2 suppressed the growth of GC cells through regulating miR‐145. SNU‐16 and AGS cells were transfected with nothing, miR‐145 inhibitor, and/or si‐circMAN2B2. si‐NC and NC inhibitor were transfected as respective controls. A, Cell viability, (B) survival, (C) apoptosis, and (D‐F) expression of caspases were respectively examined by CCK‐8 assay, colony formation assay, flow cytometry, and Western blot. \**P* \< .05](JCLA-34-e23215-g005){#jcla23215-fig-0005}

![Silence of circMAN2B2 suppressed the migration of GC cells through regulating miR‐145. SNU‐16 and AGS cells were transfected with nothing, miR‐145 inhibitor, and/or si‐circMAN2B2. si‐NC and NC inhibitor were transfected as respective controls. A, Cell migration and (B‐D) expression of MMPs were respectively examined by Transwell assay and Western blot. \**P* \< .05](JCLA-34-e23215-g006){#jcla23215-fig-0006}

3.5. Silence of circMAN2B2 regulated PI3K/AKT and JNK pathways through regulating miR‐145 {#jcla23215-sec-0023}
-----------------------------------------------------------------------------------------

To further decode the underlying mechanisms of which circMAN2B2 impacted GC cells, the expression of core factors in PI3K/AKT and JNK pathways was tested. As data presented in Figure [7](#jcla23215-fig-0007){ref-type="fig"}A‐C, the expression of active (phospho) forms of PI3K and AKT was suppressed by transfection with si‐circMAN2B2 (*P* \< .05). The impacts of si‐circMAN2B2 toward the expression of these two proteins were attenuated by miR‐145 inhibitor (*P* \< .05). Of contrast, the expression of active form (phospho) of JNK and c‐Jun was elevated by si‐circMAN2B2 (*P* \< .05), while was suppressed by miR‐145 inhibitor (*P* \< .05, Figure [7](#jcla23215-fig-0007){ref-type="fig"}D‐F).

![Silence of circMAN2B2 regulated PI3K/AKT and JNK pathways through regulating miR‐145. SNU‐16 and AGS cells were transfected with nothing, miR‐145 inhibitor, and/or si‐circMAN2B2. si‐NC and NC inhibitor were transfected as respective controls. Expression of (A‐C) PI3K, AKT, (D‐F) JNK, and c‐Jun was examined by Western blot. \**P* \< .05](JCLA-34-e23215-g007){#jcla23215-fig-0007}

4. DISCUSSION {#jcla23215-sec-0024}
=============

Over the past several years, an increasing amount of circRNAs were discovered to be involved in the progression of GC.[9](#jcla23215-bib-0009){ref-type="ref"} For instance, hsa_circ_0008035,[19](#jcla23215-bib-0019){ref-type="ref"} circCACTIN,[11](#jcla23215-bib-0011){ref-type="ref"} and circ‐DCAF6[20](#jcla23215-bib-0020){ref-type="ref"} worked as oncogenic genes in GC, while circLMTK2[21](#jcla23215-bib-0021){ref-type="ref"} and hsa_circ_0001368[22](#jcla23215-bib-0022){ref-type="ref"} functioned as tumor suppressors. These previous findings linked circRNAs with GC, which provide a better understanding of GC and showed the promise of using circRNAs as novel therapeutic targets. From the current data, circMAN2B2 was found to be high‐expressed in GC tissues as relative to paracancerous non‐tumor tissues. Therefore, a possible mechanism that knockdown of circMAN2B2 might inhibit GC development was further explored.

It has been reported that circRNAs are participated in many cancer types and play diverse influences in gene expression, apoptosis, cell cycle, etc,[23](#jcla23215-bib-0023){ref-type="ref"} GC is no exception. Multiple circRNAs were found to be specific difference between GC tissues and non‐tumor tissues[10](#jcla23215-bib-0010){ref-type="ref"} and play important role in GC carcinogenesis, such as hsa_circ_0067582,[24](#jcla23215-bib-0024){ref-type="ref"} hsa_circ_0005758,[24](#jcla23215-bib-0024){ref-type="ref"} hsa_circ_0000467,[25](#jcla23215-bib-0025){ref-type="ref"} hsa_circ_0000181 [26](#jcla23215-bib-0026){ref-type="ref"} and hsa_circ_0003159.[27](#jcla23215-bib-0027){ref-type="ref"} The present paper demonstrated that circMAN2B2 was highly expressed in GC tissues. Importantly, we verified our hypothesis that circMAN2B2 silence took an inhibitory role in GC development. Silence of circMAN2B2 significantly reduced the growth of SNU 16 and AGS cells, as evidenced by the viability loss, the repressed survival fraction and the induced apoptosis. Moreover, silence of circMAN2B2 was able to suppress the migration of GC cells. It is worth mentioning that, the impacts of circMAN2B2 silence on cell migration may due to the low expressed MMPs (MMP‐2 and MMP‐9), which are crucial in degrading extracellular matrix on cell surface and create a migration path.[28](#jcla23215-bib-0028){ref-type="ref"} These findings were consistent with the oncogenic role of circMAN2B2 in other two cancers that were reported in previous studies, that is, lung cancer[12](#jcla23215-bib-0012){ref-type="ref"} and glioma.[13](#jcla23215-bib-0013){ref-type="ref"} For the first time, we illustrated the oncogenic function of circMAN2B2 in GC, which provided a promising biomarker for monitoring and treating GC in the future.

CircRNAs could work as miRNA sponge to modulate the genes regulation. MiRNAs are another sort of newly discovered RNAs that are crucially implicated in the pathogenesis of human cancer.[14](#jcla23215-bib-0014){ref-type="ref"}, [15](#jcla23215-bib-0015){ref-type="ref"} The expression of miRNAs is related to the biological processes of human cancers, such as cell growth, proliferation, differentiation, apoptosis, metastasis, and drug‐resistance.[29](#jcla23215-bib-0029){ref-type="ref"}, [30](#jcla23215-bib-0030){ref-type="ref"}, [31](#jcla23215-bib-0031){ref-type="ref"}, [32](#jcla23215-bib-0032){ref-type="ref"} MiR‐145 is one of such miRNAs and has been reported as a tumor inhibitor in various cancers, such as cervical carcinoma,[33](#jcla23215-bib-0033){ref-type="ref"} esophageal squamous cell carcinoma (ESCC),[34](#jcla23215-bib-0034){ref-type="ref"} colorectal cancer,[35](#jcla23215-bib-0035){ref-type="ref"} prostate cancer,[36](#jcla23215-bib-0036){ref-type="ref"} and GC.[37](#jcla23215-bib-0037){ref-type="ref"} It was proved to inhibit GC cells growth, migration, and metastasis.[18](#jcla23215-bib-0018){ref-type="ref"}, [38](#jcla23215-bib-0038){ref-type="ref"} Based on the inhibitory role of circMAN2B2 silence and the reported role of miR‐145 in GC, it will be interesting to explore whether circMAN2B2 silence plays its roles in GC through regulating miR‐145. Our results showed that miR‐145 expression was up‐regulated by circMAN2B2 silence, suggesting a potential mechanism that the inhibition of miR‐145 might reverse the effects of circMAN2B2 silence on SNU 16 and AGS cells. As we expect, we found that the impact of circMAN2B2 silence was attenuated when miR‐145 was silenced simultaneously. These findings suggested that circMAN2B2 silence exerted anti‐GC impacts by up‐regulating miR‐145. Further work will be performed to explore the sponge relationship between circMAN2B2 and miR‐145 to further enrich this regulatory mechanism.

PI3K/AKT is one of the important signal transduction pathways that is greatly activated in a variety of human cancers, including GC.[39](#jcla23215-bib-0039){ref-type="ref"} Its activation confers the common features of tumor cells, like excessive growth, repressed apoptosis death and metastasis.[40](#jcla23215-bib-0040){ref-type="ref"} So, a series of inhibitors for this signaling have been developed and have entered into clinical trials.[41](#jcla23215-bib-0041){ref-type="ref"} Similar to PI3K/AKT, JNK is another widely studied signaling in cancer research.[42](#jcla23215-bib-0042){ref-type="ref"} JNK signaling can be activated by a number of stimuli such as cytokines, stress, toxins, and drugs.[43](#jcla23215-bib-0043){ref-type="ref"}, [44](#jcla23215-bib-0044){ref-type="ref"} Once activated, JNK alters the expression of multiple proteins like c‐Jun, c‐Fos, c‐Myc, and p53 to control cell proliferation, survival, death, intercellular adhesion, and migration.[42](#jcla23215-bib-0042){ref-type="ref"}, [45](#jcla23215-bib-0045){ref-type="ref"} It has been reported that miR‐145 played anti‐tumor roles through regulating PI3K/AKT and JNK pathways. For example, miR‐145 attenuated the growth and metastasis of thyroid cancer through PI3K/AKT pathway.[46](#jcla23215-bib-0046){ref-type="ref"} MiR‐145 was reported to raise the sensitivity of ESCC to cisplatin (DPP) and promote DPP‐caused apoptosis through directly inhibiting PI3K/AKT pathway.[47](#jcla23215-bib-0047){ref-type="ref"} Moreover, it could suppress epithelial‐mesenchymal transition in small cell lung cancer through regulating JNK pathway.[48](#jcla23215-bib-0048){ref-type="ref"} Therefore, based on the above regulatory mechanism between circMAN2B2 and miR‐145, circMAN2B2 might act on these two pathways. As we expect, Western blot results in this study demonstrated that silence of circMAN2B2 deactivated PI3K and AKT while activated JNK, suggesting the regulatory role of circMAN2B2 in the activation of PI3K/AKT and JNK pathways. Additionally, the regulation of circMAN2B2 on these two pathways was also through regulating miR‐145.

To sum up, this work presented the oncogenic function of circMAN2B2 in the growth and migration of GC cells. CircMAN2B2 exerted its function possibly through regulating miR‐145 and PI3K/AKT and JNK pathways. Our study provided a potential goal for the treatment of GC.
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